Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials

Published:2017-06 Issue: Volume:57 Page:8-15
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Solinas C.,Ceppi M.,Lambertini M.,Scartozzi M.,Buisseret L.,Garaud S.,Fumagalli D.,de Azambuja E.,Salgado R.,Sotiriou C.,Willard-Gallo K.,Ignatiadis M.

Funder

Belgian Fund for Scientific Research (FNRS)-Operation

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference38 articles.

1. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer;Kaufmann;Ann Surg Oncol,2012

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

3. Pathological complete response and accelerated drug approval in early breast cancer;Prowell;N Engl J Med,2012

4. Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends;Graham;Ann Surg Oncol,2015

5. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccines for breast cancer prevention: Are we there yet?;Molecular Aspects of Medicine;2024-08

2. Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer;Molecular Cancer;2024-05-10

3. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer;JAMA Oncology;2024-05-01

4. Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade;npj Breast Cancer;2024-04-18

5. Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes;Biomedicines;2024-03-29